Metallibure (INNTooltip International Nonproprietary Name) (brand names Aimax, Suisynchron, Turisynchron; former developmental code names ICI-33828, AY-61122, NSC-69536), also known as methallibure (USANTooltip United States Adopted Name, BANTooltip British Approved Name) or methallibur (German), is a medication which was introduced in 1973 and has been used in veterinary medicine to synchronize estrus.[1][2] It was withdrawn in the United States and Europe due to teratogenicity and has been replaced with altrenogest (Regumate, Matrix), a progestin.[2][3]
![]() | |
Clinical data | |
---|---|
Trade names | Aimax, Suisynchron, Turisynchron |
Other names | Methallibure; Methallibur; ICI-33828; AY-61122; NSC-69536 |
Drug class | Antigonadotropin |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.011.952 ![]() |
Chemical and physical data | |
Formula | C7H14N4S2 |
Molar mass | 218.34 g·mol−1 |
3D model (JSmol) | |
| |
|
The precise mechanism of action of metallibure is unknown.[2] It has been described as a "nonsteroidal antigonadotropin" and it appears to act directly on the pituitary gland and/or hypothalamus to suppress gonadotropin secretion.[2] However, metallibure has also been reported to be an antiprogestogen and to act specifically via inhibition of the biosynthesisorsecretionofprogesterone.[4]
Metallibure has similar endocrinological effects in women.[5] It is associated with several unpleasant side effects including appetite loss, nausea, occasional vomiting, lethargy, and drowsiness.[5] Animal toxicity studies revealed that the medication induced the development of cataracts, and this resulted in the termination of its clinical development.[5]
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |